GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer
GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer
复制标题
DOI：
10.1016/j.radonc.2004.09.004
复制
发表时间：
2005-02-01
影响因子：
5.7
通讯作者：
Bertermann, H
中科院分区：
文献类型：
--
作者：
Kovács, G;Pötter, R;Bertermann, H
背景和目的：本文的目的是介绍GEC/ESTRO-EAU对模板和经直肠超声（TRUS）引导的经会阴临时前列腺间质近距离放射治疗的建议，使用高剂量率铱-192步进源和远程后装技术。前列腺近距离放射治疗专家代表GEC/ESTRO和EAU制定了这些建议。该文件已被批准的GEC/ESTRO指导委员会成员和EAU委员会members.Patients和方法：间质性近距离放射治疗（BT）的器官局限性前列腺癌可以应用作为一个加强治疗结合外部束放射治疗（EBRT）使用适当数量的BT分数在治愈的意图。由于局部复发，临时经会阴BT单独或联合EBRT作为姑息/挽救治疗方式是可行的，但没有大量的临床经验。暂时性BT作为单一疗法的使用是正在进行的临床研究的主题。结果：治疗前调查，患者选择，设备和设施，临床团队，植入程序的建议（治疗计划和针植入）剂量和分次，报告，副作用的管理和随访。结论：这些建议的目的是技术和咨询性质，但医疗决定的最终责任在于治疗医生。虽然本文代表了跨学科专家组的共识，但TRUS和模板引导的前列腺癌临时经会阴间质植入物是一个不断发展的领域，随着新数据的出现，建议会进行修改。(c)2004爱思唯尔爱尔兰有限公司保留所有权利。
Background and purpose: The aim of this paper is to present the GEC/ESTRO-EAU recommendations for template and transrectal ultrasound (TRUS) guided transperineal temporary interstitial prostate brachytherapy using a high dose rate iridium-192 stepping source and a remote afterloading technique. Experts in prostate brachytherapy developed these recommendations on behalf of the GEC/ESTRO and of the EAU. The paper has been approved by both GEC/ESTRO steering committee members and EAU committee members.Patients and methods: Interstitial brachytherapy (BT) to organ confined prostate cancer can be applied as a boost treatment in combination with external beam radiation therapy (EBRT) using a proper number of BT fractions in curative intent. Temporary transperineal BT alone or in combination with EBRT are feasible as a palliative/salvage treatment modality because of local recurrence, however, without large clinical experience. The use of temporary BT as a monotherapy is subject of ongoing clinical research.Results: Recommendations for pre-treatment investigations, patient selection, equipment and facilities, the clinical team, the implant procedure (treatment planning and needle implantation) dose and fractionation, reporting, management of side effects and follow-up are given.Conclusions: These recommendations are intended to be technically and advisory in nature, but the ultimate responsibility for the medical decision rests with the treating physician. Although, this paper represents the consensus of an interdisciplinary group of experts, TRUS and template guided temporary transperineal interstitial implants in prostate cancer are a constantly evolving field and the recommendations are subject to modifications as new data become available. (c) 2004 Elsevier Ireland Ltd. All rights reserved.